File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

TitleRisk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy
Authors
Issue Date1998
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/
Citation
Arthritis And Rheumatism, 1998, v. 41 n. 5, p. 831-837 How to Cite?
AbstractObjective. To determine the incidence of ovarian failure after cyclophosphamide (CYC) treatment for systemic lupus erythematosus (SLE) and to identify the risk factors for this complication. Methods. The records of 70 premenopausal female SLE patients treated with CYC were reviewed retrospectively. Information on demographic features, autoantibody profiles, and CYC treatment was obtained, and comparisons were made between those who developed ovarian failure and those who did not. Data on the CYC-treated patients were also compared with data on 2 control groups of non-CYC-treated SLE patients. Results. Eighteen patients developed ovarian failure after CYC treatment, for an overall incidence of 26%. The incidence of ovarian failure showed a linear trend of increase with increasing age at the start of CYC (P = 0.007). The cumulative CYC dose was significantly higher in the patients with ovarian failure than in those without (28.3 gm versus 15.4 gm; P = 0.004). The risk of ovarian failure also showed a linear trend of increase with increasing cumulative CYC dose (P < 0.001). Using multiple logistic regression, the age at the time of CYC treatment initiation (β = 0.37, SE = 0.11, P = 0.001) and the cumulative dose of CYC received (β = 0.69, SE = 0.29, P = 0.02) were found to be independent risk factors for CYC-induced ovarian failure. Conclusion. In our population of female SLE patients, CYC- induced ovarian toxicity is a significant problem, particularly in patients above the age of 40. The age at the start of CYC therapy and the cumulative dose are the major determinants for the development of this complication. For older patients with SLE in whom the use of CYC is warranted, a shorter course and lower dosage should be considered.
Persistent Identifierhttp://hdl.handle.net/10722/161626
ISSN
2015 Impact Factor: 8.955
2015 SCImago Journal Rankings: 3.206
References

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_US
dc.contributor.authorLau, CSen_US
dc.contributor.authorWong, RWSen_US
dc.date.accessioned2012-09-05T05:13:13Z-
dc.date.available2012-09-05T05:13:13Z-
dc.date.issued1998en_US
dc.identifier.citationArthritis And Rheumatism, 1998, v. 41 n. 5, p. 831-837en_US
dc.identifier.issn0004-3591en_US
dc.identifier.urihttp://hdl.handle.net/10722/161626-
dc.description.abstractObjective. To determine the incidence of ovarian failure after cyclophosphamide (CYC) treatment for systemic lupus erythematosus (SLE) and to identify the risk factors for this complication. Methods. The records of 70 premenopausal female SLE patients treated with CYC were reviewed retrospectively. Information on demographic features, autoantibody profiles, and CYC treatment was obtained, and comparisons were made between those who developed ovarian failure and those who did not. Data on the CYC-treated patients were also compared with data on 2 control groups of non-CYC-treated SLE patients. Results. Eighteen patients developed ovarian failure after CYC treatment, for an overall incidence of 26%. The incidence of ovarian failure showed a linear trend of increase with increasing age at the start of CYC (P = 0.007). The cumulative CYC dose was significantly higher in the patients with ovarian failure than in those without (28.3 gm versus 15.4 gm; P = 0.004). The risk of ovarian failure also showed a linear trend of increase with increasing cumulative CYC dose (P < 0.001). Using multiple logistic regression, the age at the time of CYC treatment initiation (β = 0.37, SE = 0.11, P = 0.001) and the cumulative dose of CYC received (β = 0.69, SE = 0.29, P = 0.02) were found to be independent risk factors for CYC-induced ovarian failure. Conclusion. In our population of female SLE patients, CYC- induced ovarian toxicity is a significant problem, particularly in patients above the age of 40. The age at the start of CYC therapy and the cumulative dose are the major determinants for the development of this complication. For older patients with SLE in whom the use of CYC is warranted, a shorter course and lower dosage should be considered.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/en_US
dc.relation.ispartofArthritis and Rheumatismen_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAmenorrhea - Chemically Induceden_US
dc.subject.meshAntirheumatic Agents - Adverse Effectsen_US
dc.subject.meshCyclophosphamide - Adverse Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshLupus Erythematosus, Systemic - Blood - Drug Therapy - Pathologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrimary Ovarian Insufficiency - Chemically Induceden_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.titleRisk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapyen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1en_US
dc.identifier.pmid9588734-
dc.identifier.scopuseid_2-s2.0-0010006795en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0010006795&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume41en_US
dc.identifier.issue5en_US
dc.identifier.spage831en_US
dc.identifier.epage837en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridMok, CC=34668219600en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridWong, RWS=34875928200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats